EP3515492A4 - Anti-cancer agents and preparation thereof - Google Patents
Anti-cancer agents and preparation thereof Download PDFInfo
- Publication number
- EP3515492A4 EP3515492A4 EP17853991.2A EP17853991A EP3515492A4 EP 3515492 A4 EP3515492 A4 EP 3515492A4 EP 17853991 A EP17853991 A EP 17853991A EP 3515492 A4 EP3515492 A4 EP 3515492A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation
- cancer agents
- cancer
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662398783P | 2016-09-23 | 2016-09-23 | |
PCT/US2017/052967 WO2018057897A1 (en) | 2016-09-23 | 2017-09-22 | Anti-cancer agents and preparation thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3515492A1 EP3515492A1 (en) | 2019-07-31 |
EP3515492A4 true EP3515492A4 (en) | 2020-04-08 |
EP3515492B1 EP3515492B1 (en) | 2023-07-26 |
Family
ID=61690726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17853991.2A Active EP3515492B1 (en) | 2016-09-23 | 2017-09-22 | Anti-cancer agents and preparation thereof |
Country Status (14)
Country | Link |
---|---|
US (2) | US10858371B2 (en) |
EP (1) | EP3515492B1 (en) |
JP (1) | JP7111722B2 (en) |
KR (1) | KR102646702B1 (en) |
CN (1) | CN109862916A (en) |
AU (1) | AU2017331260A1 (en) |
BR (1) | BR112019005885A2 (en) |
CA (1) | CA3037883A1 (en) |
DK (1) | DK3515492T3 (en) |
IL (1) | IL265521B1 (en) |
MA (1) | MA46291A (en) |
MX (1) | MX2019003368A (en) |
RU (1) | RU2019111768A (en) |
WO (1) | WO2018057897A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017331260A1 (en) | 2016-09-23 | 2019-05-16 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901464A (en) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Process for obtaining vanillin |
US7825267B2 (en) * | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
WO2009031999A1 (en) * | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fr901464 and analogs with antitumor activity and method for their preparation |
CN101417934B (en) * | 2007-10-24 | 2012-04-18 | 国鼎生物科技股份有限公司 | New compounds separated from Antrodia camphorate extract |
ES2545977T3 (en) | 2008-03-18 | 2015-09-17 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
US8969405B2 (en) * | 2008-06-21 | 2015-03-03 | St. Jude Children's Research Hospital | Anticancer compounds and methods of making and using same |
US20150025017A1 (en) * | 2012-02-28 | 2015-01-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating cancer |
AU2013340449B2 (en) * | 2012-11-05 | 2017-11-30 | Pfizer Inc. | Spliceostatin analogs |
WO2014100367A1 (en) * | 2012-12-21 | 2014-06-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
US20140274979A1 (en) * | 2013-03-13 | 2014-09-18 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
AU2014292132B2 (en) | 2013-07-15 | 2018-11-08 | Marcus Conrad | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death |
KR102092569B1 (en) * | 2013-09-17 | 2020-03-25 | 엘지디스플레이 주식회사 | Display Device Integrated With Touch Screen and Method for Driving The Same |
CA2931111C (en) * | 2013-11-19 | 2022-03-15 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
MA45258A (en) * | 2016-06-08 | 2019-04-17 | Univ Rice William M | THAILANSTATINE A DERIVATIVES, METHODS OF TREATMENT AND METHODS OF SYNTHESIS THEREOF |
AU2017331260A1 (en) | 2016-09-23 | 2019-05-16 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2017
- 2017-09-22 AU AU2017331260A patent/AU2017331260A1/en active Pending
- 2017-09-22 MA MA046291A patent/MA46291A/en unknown
- 2017-09-22 KR KR1020197011144A patent/KR102646702B1/en active IP Right Grant
- 2017-09-22 WO PCT/US2017/052967 patent/WO2018057897A1/en unknown
- 2017-09-22 BR BR112019005885-0A patent/BR112019005885A2/en unknown
- 2017-09-22 JP JP2019537750A patent/JP7111722B2/en active Active
- 2017-09-22 EP EP17853991.2A patent/EP3515492B1/en active Active
- 2017-09-22 MX MX2019003368A patent/MX2019003368A/en unknown
- 2017-09-22 CA CA3037883A patent/CA3037883A1/en active Pending
- 2017-09-22 DK DK17853991.2T patent/DK3515492T3/en active
- 2017-09-22 IL IL265521A patent/IL265521B1/en unknown
- 2017-09-22 US US16/335,378 patent/US10858371B2/en active Active
- 2017-09-22 RU RU2019111768A patent/RU2019111768A/en unknown
- 2017-09-22 CN CN201780065546.7A patent/CN109862916A/en active Pending
-
2020
- 2020-11-09 US US17/092,829 patent/US11851441B2/en active Active
Non-Patent Citations (1)
Title |
---|
No further relevant documents disclosed * |
Also Published As
Publication number | Publication date |
---|---|
US10858371B2 (en) | 2020-12-08 |
US20190218228A1 (en) | 2019-07-18 |
EP3515492A1 (en) | 2019-07-31 |
MX2019003368A (en) | 2019-09-16 |
EP3515492B1 (en) | 2023-07-26 |
KR102646702B1 (en) | 2024-03-11 |
US20210395265A1 (en) | 2021-12-23 |
WO2018057897A1 (en) | 2018-03-29 |
BR112019005885A2 (en) | 2020-06-02 |
JP2019529563A (en) | 2019-10-17 |
RU2019111768A3 (en) | 2020-11-24 |
CN109862916A (en) | 2019-06-07 |
JP7111722B2 (en) | 2022-08-02 |
KR20190077340A (en) | 2019-07-03 |
CA3037883A1 (en) | 2018-03-29 |
IL265521B1 (en) | 2024-05-01 |
AU2017331260A1 (en) | 2019-05-16 |
US11851441B2 (en) | 2023-12-26 |
DK3515492T3 (en) | 2023-08-28 |
RU2019111768A (en) | 2020-10-23 |
IL265521A (en) | 2019-05-30 |
MA46291A (en) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3529279A4 (en) | Cd133-binding agents and uses thereof | |
EP3303379A4 (en) | Tigit-binding agents and uses thereof | |
EP3253890A4 (en) | Tnfrsf-binding agents and uses thereof | |
EP3334706A4 (en) | Pillararenes and uses thereof | |
EP3283516A4 (en) | Anti-pacap antibodies and uses thereof | |
EP3253373A4 (en) | Lipid nanoparticles and uses thereof | |
EP3503879A4 (en) | Compositions and methods thereof | |
EP3142705A4 (en) | Polymer-flavonoid conjugate and uses thereof | |
EP3416647A4 (en) | N3-substituted iminopyrimidinones as antimalarial agents | |
EP3511407A4 (en) | Christensenella intestinihominis and application thereof | |
EP3307265A4 (en) | Pharmaceutical combination and uses thereof | |
EP3285805A4 (en) | Therapeutic antibodies and uses thereof | |
EP3560517A4 (en) | Aptamer-drug conjugate and use thereof | |
EP3191114A4 (en) | Occidiofungin formulations and uses thereof | |
EP3526215A4 (en) | N-acylethanolamide derivatives and uses thereof | |
EP3071563A4 (en) | Anti-cancer agents and preparation thereof | |
AU2016349786B2 (en) | Anti-CD3-folate conjugates and their uses | |
EP3383401A4 (en) | Thieno-pyrimidine derivatives and uses thereof | |
EP3551184A4 (en) | Anti-cancer compounds and uses thereof | |
EP3471711A4 (en) | Antimalarial compositions and uses thereof | |
EP3264891A4 (en) | Etv2 and uses thereof | |
EP3541405A4 (en) | Novel antimicrobial and anti-cancer therapy | |
EP3302483A4 (en) | Pharmaceutical compositions and use thereof | |
EP3302513A4 (en) | Composition and uses thereof | |
EP3542796A4 (en) | Compound having anti-cancer effect, and preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190415 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PURDUE RESEARCH FOUNDATION |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GHOSH, ARUN K. |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602017071910 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0039395000 Ipc: C07D0309140000 Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0039395000 Ipc: C07D0309140000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200305 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101ALI20200228BHEP Ipc: A61K 31/337 20060101ALI20200228BHEP Ipc: A61K 31/517 20060101ALI20200228BHEP Ipc: A61P 35/00 20060101ALI20200228BHEP Ipc: C07D 309/14 20060101AFI20200228BHEP Ipc: C07D 493/10 20060101ALI20200228BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20201203 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230224 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PURDUE RESEARCH FOUNDATION |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017071910 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20230825 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230926 Year of fee payment: 7 Ref country code: IE Payment date: 20230927 Year of fee payment: 7 Ref country code: GB Payment date: 20230927 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230925 Year of fee payment: 7 Ref country code: DK Payment date: 20230927 Year of fee payment: 7 Ref country code: DE Payment date: 20230927 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1591827 Country of ref document: AT Kind code of ref document: T Effective date: 20230726 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231027 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231127 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231026 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231126 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231027 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20231004 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017071910 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 |
|
VS25 | Lapsed in a validation state [announced via postgrant information from nat. office to epo] |
Ref country code: MD Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230922 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230922 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230726 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |